by Sabah Sallah, and Jim Y. Wan

Slides:



Advertisements
Similar presentations
RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.
Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.
Phenotypic and Functional Changes Induced at the Clonal Level in Hematopoietic Stem Cells After 5-Fluorouracil Treatment by Troy D. Randall, and Irving.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
How I treat extramedullary myeloma
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Mast cell leukemia by Sophie Georgin-Lavialle, Ludovic Lhermitte, Patrice Dubreuil, Marie-Olivia Chandesris, Olivier Hermine, and Gandhi Damaj Blood Volume.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.
Hydroxyurea makes inflammation “just right”?
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma by Shigesaburo Miyakoshi, Masahiro Kami,
by Henrik Frederiksen, and Kai Schmidt
by Timothy P. Hughes, and David M. Ross
Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.
by James O. Armitage, and Dan L. Longo
How I treat autoimmune hemolytic anemias in adults
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Transplants for the elderly in myeloma
How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
Critiquing Cryos by Morie Gertz Blood Volume 111(11):
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model.
Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.
Engineering regulatory T cells against factor VIII inhibitors
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Acute promyelocytic leukemia, microgranular variant
Induction of tolerance to human factor VIII in mice
How we choose factor VIII to treat hemophilia
by Alexander Röth, Andreas Hüttmann, Russell P
by Ernest Beutler Blood Volume 98(9): November 1, 2001
An actuarial GPS for hemophilic longevity
Taking a leaf from the book of oral tolerance
by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Stage C or not stage C…? by Claire Dearden Blood
by Cornelis van 't Veer, Neal J. Golden, and Kenneth G. Mann
by Ineke J. M. ten Berge, and René A. W. van Lier
Blocking VWF platelet binding to treat TTP
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.
HU for acute treatment of sickle VOC?
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
How I treat refractory CLL
Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.
Anergy: the CLL cell limbo
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab.
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
by Christine L. Kempton, and Amanda B. Payne
by Wendy Lim, Sara K. Vesely, and James N. George
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Overcoming “aspirin resistance” in MPN
Treatment versus Transplant for Challenging Hematologic Disorders
Volume 2(Supplement 1):39-41
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors by Midori Shima, Hideji Hanabusa,
How I treat unexplained refractory iron deficiency anemia
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
How I treat heparin-induced thrombocytopenia and thrombosis
In Memoriam: E. Donnall Thomas
Pure red cell aplasia by Robert T. Means Blood
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
by Lapo Alinari, and Kristie A. Blum
Initial treatment of CLL: integrating biology and functional status
Cold agglutinin disease
New concepts for anticoagulant therapy in persons with hemophilia
Presentation transcript:

by Sabah Sallah, and Jim Y. Wan Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia by Sabah Sallah, and Jim Y. Wan Blood Volume 101(3):943-945 February 1, 2003 ©2003 by American Society of Hematology

The course of factor VIII inhibitor and factor VIII level in 6 patients with inhibitors against factor VIII.Day 0 corresponds to the first day of treatment with 2-chlorodeoxyadenosine. The course of factor VIII inhibitor and factor VIII level in 6 patients with inhibitors against factor VIII.Day 0 corresponds to the first day of treatment with 2-chlorodeoxyadenosine. Sabah Sallah, and Jim Y. Wan Blood 2003;101:943-945 ©2003 by American Society of Hematology